AstraZeneca Surpasses Q2 Profit Expectations, Maintains Outlook
AstraZeneca exceeded second-quarter profit expectations and reaffirmed its 2026 forecasts on Monday, driven by demand for its therapies. The drugmaker aimed to address concerns regarding its longer-term growth prospects following a recent trial failure. Despite robust demand for therapies targeting cancer and rare diseases propelling growth for the pharmaceutical giant in the face of pricing pressures, an unforeseen trial failure this month has shifted focus to its drug pipeline and raised concerns about the sustainability of its long-term revenue targets.
The company’s core earnings for the three months ended June 30 increased by 18 percent to $2.63 per share, while total revenue experienced a 5 percent rise to $15.38 billion at constant-currency rates. Analysts, on average, anticipated earnings of $2.48 per share alongside revenues of $15.39 billion, as per a consensus compiled by the company.
AstraZeneca continues to anticipate that core earnings per share will rise by a low double-digit percentage by 2026, while total revenues are projected to grow at a mid-to-high-single-digit rate. In 2025, it reported a sales growth of approximately 8 percent and a profit growth of around 11 percent, respectively.
